What is Chardan Capital's Estimate for STOK FY2025 Earnings?

Key Points

• Chardan Capital lowered its FY2025 earnings per share (EPS) forecast for Stoke Therapeutics from $0.45 to $0.40, while maintaining a "Buy" rating with a target price of $24.00.
• Stoke Therapeutics reported a quarterly EPS of ($0.40), exceeding analysts' estimates of ($0.57), with revenues of $13.82 million compared to an expected $31.51 million.
• The company currently has a consensus rating of "Buy" from analysts, with an average price target of $25.17.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Chardan Capital analyst R. Li now anticipates that the company will earn $0.40 per share for the year, down from their prior forecast of $0.45. Chardan Capital currently has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Chardan Capital also issued estimates for Stoke Therapeutics' FY2026 earnings at ($2.30) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.

Several other research analysts have also recently weighed in on STOK. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Wedbush boosted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. Finally, BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Stock Down 0.6%

Shares of Stoke Therapeutics stock traded down $0.12 on Monday, hitting $19.56. 1,149,629 shares of the company were exchanged, compared to its average volume of 867,662. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of 23.01 and a beta of 1.15. The company has a 50-day moving average price of $13.31 and a 200 day moving average price of $10.43. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $19.91.

Insider Buying and Selling

In other news, insider Barry Ticho sold 4,504 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $12.82, for a total transaction of $57,741.28. Following the completion of the sale, the insider owned 16,775 shares in the company, valued at $215,055.50. This trade represents a 21.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 13,712 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $15.00, for a total transaction of $205,680.00. Following the completion of the transaction, the general counsel owned 19,631 shares in the company, valued at approximately $294,465. This represents a 41.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,432 shares of company stock valued at $345,775 in the last 90 days. Insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. JPMorgan Chase & Co. lifted its holdings in shares of Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after acquiring an additional 4,512 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Stoke Therapeutics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 877,095 shares of the company's stock valued at $9,677,000 after acquiring an additional 6,264 shares during the period. Wells Fargo & Company MN boosted its holdings in Stoke Therapeutics by 51.2% during the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock valued at $185,000 after acquiring an additional 5,682 shares during the period. Invesco Ltd. purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $133,000. Finally, Renaissance Technologies LLC purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $1,423,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.